 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || holybuvir (SH-229) / Nanjing Sanhome Pharma
PK/PD data, Journal: Single-Ascending-Dose, Food-Effect, and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of the Pangenotypic Anti-Hepatitis C Virus Drug Holybuvir in Healthy Chinese Subjects. (Pubmed Central) - Mar 20, 2023
The favorable PK and safety results support the further development of holybuvir for patients with HCV. (This study was registered at Chinadrugtrials.org under identifier CTR20170859.).
- Daklinza (daclatasvir) / BMS, holybuvir (SH-229) / Nanjing Sanhome Pharma
[VIRTUAL] SH229 plus daclatasvir for treatment of chronic hepatitis C virus infection in China: a single-arm, open-label, phase 3 study (Poster area) - Apr 9, 2021 - Abstract #EASLILC2021EASL_ILC_1231;
(This study was registered at Chinadrugtrials.org under identifier CTR20170859.). Treatment with the pan-genotypic regimen of SH229 plus daclatasvir for 12 weeks was highly effective and safe in Chinese patients infected with HCV genotype 1, 2, 3, or 6, suggesting this regimen could be a promising option for HCV treatment in China irrespective of genotype.
- Daklinza (daclatasvir) / BMS, holybuvir (SH-229) / Nanjing Sanhome Pharma
[VIRTUAL] A phase 2, open-label study of pan-genotype regimen of SH229 plus daclatasvir in Chinese patients with chronic hepatitis C virus infection (Poster Area) - May 30, 2020 - Abstract #EASLILCI2020EASL-ILC-I-795;
Treatment with the pan-genotypic regimen of SH229 plus daclatasvir for 12 weeks was highly effective and safe in Chinese patients infected with HCV genotype 1, 2, 3, or 6, suggesting this regimen could be a promising option for HCV treatment in China irrespective of genotype. Once-daily oral administration of SH229 plus daclatasvir were highly effective and safe in Chinese patients infected with HCV genotype 1, 2, 3, or 6, suggesting SH229 could be a promising drug candidate for HCV treatment in China irrespective of genotype.
- Daklinza (daclatasvir) / BMS, holybuvir (SH-229) / Nanjing Sanhome Pharma
A phase 2, open-label study of pan-genotype regimen of sh229 plus daclatasvir in chinese patients with chronic hepatitis c virus infection (Poster Area) - Feb 2, 2020 - Abstract #EASLILC2020EASL-ILC_1171;
- | holybuvir (SH-229) / Nanjing Sanhome Pharma
New P2/3 trial: SH229 Tablets Combined With Daclatasvir Dihydrochloride Tablets in Treatment Adult Patients With Chronic Hepatitis C (clinicaltrials.gov) - Aug 28, 2019
P2/3, N=440, Active, not recruiting, Sponsor: Nanjing Sanhome Pharmaceutical, Co., Ltd.
- | holybuvir (SH-229) / Nanjing Sanhome Pharma
Trial completion: A Drug-drug Interaction Study of SH229 Tablets and Daclatasvir Dihydrochloride Tablets in Healthy Subjects (clinicaltrials.gov) - Aug 14, 2019
P1, N=28, Completed, Sponsor: Nanjing Sanhome Pharmaceutical, Co., Ltd.
Once-daily oral administration of SH229 plus daclatasvir were highly effective and safe in Chinese patients infected with HCV genotype 1, 2, 3, or 6, suggesting SH229 could be a promising drug candidate for HCV treatment in China irrespective of genotype. Active, not recruiting --> Completed
- | holybuvir (SH-229) / Nanjing Sanhome Pharma
Enrollment closed: A Drug-drug Interaction Study of SH229 Tablets and Daclatasvir Dihydrochloride Tablets in Healthy Subjects (clinicaltrials.gov) - Nov 29, 2018
P1, N=28, Active, not recruiting, Sponsor: Nanjing Sanhome Pharmaceutical, Co., Ltd.
Active, not recruiting --> Completed Not yet recruiting --> Active, not recruiting
- | holybuvir (SH-229) / Nanjing Sanhome Pharma
New P1 trial: A Drug-drug Interaction Study of SH229 Tablets and Daclatasvir Dihydrochloride Tablets in Healthy Subjects (clinicaltrials.gov) - Nov 21, 2018
P1, N=28, Not yet recruiting, Sponsor: Nanjing Sanhome Pharmaceutical, Co., Ltd.
- | holybuvir (SH-229) / Nanjing Sanhome Pharma
Trial completion: Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of SH229 in Patients With HCV Infection (clinicaltrials.gov) - Aug 28, 2018
P1, N=30, Completed, Sponsor: Nanjing Sanhome Pharmaceutical, Co., Ltd.
Not yet recruiting --> Active, not recruiting Enrolling by invitation --> Completed
- | holybuvir (SH-229) / Nanjing Sanhome Pharma
New P1 trial: Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of SH229 in Patients With HCV Infection (clinicaltrials.gov) - Jul 16, 2018
P1, N=30, Enrolling by invitation, Sponsor: Nanjing Sanhome Pharmaceutical, Co., Ltd.